rat anti pd l1  (Bio X Cell)

Journal: bioRxiv

Article Title: A single injection of anti-PD-L1 blocking antibody induces a transient reduction in tau pathology in P301S (PS19) mouse model of tauopathy

doi: 10.1101/2025.09.28.679024

Figure Lengend Snippet: 7–8-month-old PS19 mice injected with either 0.1 or 1.5mg/mouse anti-PD-L1 antibody (short half-life variant) were tested for (a) PD-1 expression on blood-borne memory (CD44 + ) CD4 T cells on day 3 after injection. Isotype control injected mice and non-transgenic (WT) untreated mice served as controls. n=2-3 per group; one-way ANOVA followed by Fischer post-hoc test; error bars represent mean ± SEM; **, p< 0.01 between indicated groups. In a separate group of mice, (b) time spent in the novel arm of a T-maze was determined at baseline (8 months old; before drug administration) and on days 14 and 26 following injection. Total Tau (MAPT) levels were calculated using HTRF in (c) cortex and (d) CSF on day 28 after treatment. n=5-11 per group; two-way ANOVA followed by Dunnett’s multiple comparisons test; error bars represent mean ± SEM; **, p< 0.01 between indicated groups.

Article Snippet: The second was a rat anti-mouse PD-L1 monoclonal antibody (clone 10F.9G2, IgG2b isotype; Bio X Cell).

Techniques: Injection, Variant Assay, Expressing, Control, Transgenic Assay

Journal: bioRxiv

Article Title: A single injection of anti-PD-L1 blocking antibody induces a transient reduction in tau pathology in P301S (PS19) mouse model of tauopathy

doi: 10.1101/2025.09.28.679024

Figure Lengend Snippet: PS19 mice received either 1.5mg/mouse anti-PD-L1 blocking antibody or isotype control at 5-6 months of age. Non-transgenic (WT) littermates were used as a negative control. (a) Cortical and (b) hippocampal levels of S404 hyperphosphorylated Tau protein were measured using HTRF on days 14 and 28 following injection. (c) CSF and (d) serum levels of NfL were measured using ELISA or SIMOA, respectively. n=5-6 per group; one-way ANOVA followed by Fischer post-hoc test; error bars represent mean ± SEM; **, p< 0.01; ***, p< 0.001; ns = non-significant, between indicated groups.

Article Snippet: The second was a rat anti-mouse PD-L1 monoclonal antibody (clone 10F.9G2, IgG2b isotype; Bio X Cell).

Techniques: Blocking Assay, Control, Transgenic Assay, Negative Control, Injection, Enzyme-linked Immunosorbent Assay

Journal: bioRxiv

Article Title: A single injection of anti-PD-L1 blocking antibody induces a transient reduction in tau pathology in P301S (PS19) mouse model of tauopathy

doi: 10.1101/2025.09.28.679024

Figure Lengend Snippet: Male and female 9-month-old PS19 mice were treated with either 1.5mg/mouse anti-PD-L1 blocking antibody or isotype control. Non-transgenic (WT) littermates were used as a negative control. (a) Levels of Tau protein phosphorylation on S202/T205 or S404 measured in the brain cortices of male and female PS19 (Tg) mice 14 days after treatment. Grey area shows standard error margins of levels measured in WT untreated mice. CSF levels of (b) total Tau (MAPT) and (c) NfL were measured on day 14 following injection in the same experiment. n=8-11 per group; one-way ANOVA followed by Fischer post-hoc test; error bars represent mean ± SEM; *, p< 0.05; **, p< 0.01; ***, p< 0.001 between indicated groups.

Article Snippet: The second was a rat anti-mouse PD-L1 monoclonal antibody (clone 10F.9G2, IgG2b isotype; Bio X Cell).

Techniques: Blocking Assay, Control, Transgenic Assay, Negative Control, Phospho-proteomics, Injection

Journal: bioRxiv

Article Title: A single injection of anti-PD-L1 blocking antibody induces a transient reduction in tau pathology in P301S (PS19) mouse model of tauopathy

doi: 10.1101/2025.09.28.679024

Figure Lengend Snippet: PS19 mice were cross-bred with Trem2 -/- (knock-out (KO)) mice. Isotype control or anti-PD-L1 (1.5mg/mouse) antibody were administered to KO mice at the age of 7 months, and cognitive performance was tested 28 days later in (a) T-maze exploration, and (b) novel object recognition tasks. (c) Cortical levels of S404 Tau phosphorylation were measured using HTRF assay. n=6-8 per group; one-way ANOVA followed by Fischer post-hoc test; error bars represent mean ± SEM; *, p< 0.05; **, p< 0.01; between indicated groups. (d) A separate group of PS19 mice on a Trem2 -/- background were treated with anti-PD-L1 at the age of 8-9 months and tested for changes in cognitive performance using the novel object recognition task. n=5-6 per group; one-way ANOVA followed by Fischer post-hoc test; error bars represent mean ± SEM; ***, p< 0.001; between indicated groups.

Article Snippet: The second was a rat anti-mouse PD-L1 monoclonal antibody (clone 10F.9G2, IgG2b isotype; Bio X Cell).

Techniques: Knock-Out, Control, Phospho-proteomics, HTRF Assay